Inhibition of Rho kinases enhances the degradation of mutant huntingtin.
about
The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's diseaseRho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarityPotential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseasesIntravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington diseaseConserved role for autophagy in Rho1-mediated cortical remodeling and blood cell recruitment.Rho-associated kinase activity is required for proper morphogenesis of the inner cell mass in the mouse blastocyst.Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activationF-actin binding regions on the androgen receptor and huntingtin increase aggregation and alter aggregate characteristicsAutophagy and SQSTM1 on the RHOA(d) again: emerging roles of autophagy in the degradation of signaling proteins.A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS.The Rho kinase inhibitor Fasudil up-regulates astrocytic glutamate transport subsequent to actin remodelling in murine cultured astrocytes.Transcriptomic analysis and 3D bioengineering of astrocytes indicate ROCK inhibition produces cytotrophic astrogliosis.Large-scale RNA interference screening in mammalian cells identifies novel regulators of mutant huntingtin aggregation.Toward understanding Machado-Joseph diseaseROCK-phosphorylated vimentin modifies mutant huntingtin aggregation via sequestration of IRBIT.Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal DegenerationRho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress.A large scale Huntingtin protein interaction network implicates Rho GTPase signaling pathways in Huntington disease.Accelerators, Brakes, and Gears of Actin Dynamics in Dendritic Spines.Role of androgen receptor polyQ chain elongation in Kennedy's disease and use of natural osmolytes as potential therapeutic targets.Potential therapeutic targets in polyglutamine-mediated diseases.Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease.Transcriptomic profiling of astrocytes treated with the Rho kinase inhibitor fasudil reveals cytoskeletal and pro-survival responses.Chatting with the neighbors: crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders.Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts.Vaccinia-Related Kinase 2 Controls the Stability of the Eukaryotic Chaperonin TRiC/CCT by Inhibiting the Deubiquitinating Enzyme USP25Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process.Rho-kinase inhibitor Y-27632 attenuates arsenic trioxide toxicity in H9c2 cardiomyoblastoma cells.Coupling of D2R Short but not D2R Long receptor isoform to the Rho/ROCK signaling pathway renders striatal neurons vulnerable to mutant huntingtin.Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain.Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases.Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.Approaches for discovering novel bioactive small molecules targeting autophagy.Disruption of ROCK1 gene restores autophagic flux and mitigates doxorubicin-induced cardiotoxicity.Disruption of ROCK1 gene restores autophagic flux and mitigates doxorubicin-induced cardiotoxicity.Therapeutic effect of Rho kinase inhibitor FSD-C10 in a mouse model of Alzheimer's disease
P2860
Q24293871-4630D0EB-6E1A-4FCE-8360-DC7552899600Q24298069-6910E35F-3EDF-4A75-BBE9-39976BA81135Q28391383-6B9D0572-112B-45D9-8A66-A6E4CDC05B2DQ28486105-A6E729A0-0631-403F-AA35-B39288F541BFQ30495074-82A1DD0C-2403-43D4-A064-9DBE1585B763Q30650902-0F1567FC-CC59-4D4A-B7DB-E0DC9E077E3CQ33519066-9136294D-034A-443B-A0A6-6267F7D079C9Q33530121-87DB671A-F904-4F04-8D2A-49BE07A5EBADQ33577569-68A6571C-7FEF-43FB-B094-F8963824489DQ33640604-34C56120-BA84-4A2C-A4C7-A2E1C5C97418Q33720369-4214FB79-732A-43E9-9B83-ADADDE58F5A5Q35005676-BB2C9A31-D362-40F7-BA1F-F608C48C8BCEQ35103816-BB0D0204-28DF-48D9-BA80-DDB3C2A86E1CQ35140529-63FE2F40-1CCB-4A91-9E9A-E11E620201D0Q35837355-C7F4E6BB-3AF9-410B-8605-AFFE5F44EE26Q36411728-9565B372-39AE-456D-AC76-CF48FC586DE7Q36507768-190724EB-8BCA-48EA-9EB4-3DDBDF3CB0E5Q36772887-51D81313-5492-4B47-AD48-89426C518DAFQ37088020-4CD98D6C-A582-4B33-9B01-8A854BFF1173Q37622579-5C849224-C334-47C0-92E0-BB23B9056C8EQ37750482-5085DC85-C0CD-4456-81FA-2FFC558EBEF3Q38048236-CF116E5A-FF39-4568-AAC2-E8DC07EB5483Q38246221-F965DF7E-92A3-49CC-B84C-71FEA3DD0D09Q38260925-1FF3D808-8C84-436E-9883-DA787BE8D611Q38502206-0B038E0E-0D30-4B53-A429-4E11C1A5C7C1Q38530085-1A1904B0-610C-4991-A911-560C354099D1Q38792714-D4EED796-3559-40F2-941D-155B91FA6E32Q38901759-A5E14981-C4CA-4774-A37A-078179F5921AQ39112084-B863E48A-7468-4DDF-A74D-105C9EF2FB96Q39175196-E8E42D6E-69B6-469D-970B-287EB4DF7A07Q39311622-27BAFF5F-3421-48BE-A64B-C9085B4B4FDEQ42365681-5D4A1A89-7120-4608-A602-6F9A79A574B2Q45295696-3F3700B8-B632-40F3-BEC6-6D05936CC9BAQ45735441-F6101F12-7114-4A1E-BDEF-8D03191D5A28Q47280331-6F9C0B99-24DE-415D-BC0A-53D0E86FC392Q48708365-D23799E5-A05A-4DFF-9509-5EE3538DD5D8Q51737451-79BB0E83-F8D1-410A-984E-E5E416D350F4Q55308870-697C970D-56AF-4FA4-A47B-FC4E8BDFDB74Q57787052-CD7B6ADC-6826-4841-92F9-C1FD656304EF
P2860
Inhibition of Rho kinases enhances the degradation of mutant huntingtin.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Inhibition of Rho kinases enhances the degradation of mutant huntingtin.
@en
Inhibition of Rho kinases enhances the degradation of mutant huntingtin.
@nl
type
label
Inhibition of Rho kinases enhances the degradation of mutant huntingtin.
@en
Inhibition of Rho kinases enhances the degradation of mutant huntingtin.
@nl
prefLabel
Inhibition of Rho kinases enhances the degradation of mutant huntingtin.
@en
Inhibition of Rho kinases enhances the degradation of mutant huntingtin.
@nl
P2093
P2860
P50
P356
P1476
Inhibition of Rho kinases enhances the degradation of mutant huntingtin
@en
P2093
Anand Goswami
Haruko Miyazaki
Misako Okuno
Nobuyuki Nukina
Yoshihiro Kino
P2860
P304
13153-13164
P356
10.1074/JBC.M809229200
P407
P577
2009-03-11T00:00:00Z